Edgewise Therapeutics, Inc. (EWTX)
$42.76-$1.43 (-3.24%) Today
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 21 | 243,429 | $9.78M |
| Grant or award | 26 | 1,271,763 | |
| Option exercise | 24 | 582,496 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
47 Form 4 filings on record, the earliest from Oct 16, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jonathan C. Fox | Grant or award | Common Stock | 728 | $0.00 | - | |
| Alan J. Russell - Officer | Option exercise | Common Stock | 100,000 | $0.18 | $18K | |
| Alan J. Russell - Officer | Open-market sale | Common Stock | 100,000 | $14.60 | $1.46M | |
| Alan J. Russell - Officer | Option exercise | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Joanne M. Donovan - Officer | Option exercise | Common Stock | 5,781 | $0.00 | - | |
| Joanne M. Donovan - Officer | Open-market sale | Common Stock | 2,862 | $13.39 | $38K | |
| Joanne M. Donovan - Officer | Option exercise | Restricted Stock Units | 5,781 | $0.00 | - | |
| Joanne M. Donovan - Officer | Grant or award | Restricted Stock Units | 28,125 | $0.00 | - | |
| Joanne M. Donovan - Officer | Grant or award | Stock Option (Right to Buy) | 168,750 | $0.00 | - | |
| Behrad Derakhshan - Officer | Option exercise | Common Stock | 5,781 | $0.00 | - | |
| Behrad Derakhshan - Officer | Open-market sale | Common Stock | 2,491 | $13.39 | $33K | |
| Behrad Derakhshan - Officer | Option exercise | Restricted Stock Units | 5,781 | $0.00 | - | |
| Behrad Derakhshan - Officer | Grant or award | Restricted Stock Units | 30,000 | $0.00 | - | |
| Behrad Derakhshan - Officer | Grant or award | Stock Option (Right to Buy) | 180,000 | $0.00 | - | |
| Robert Blaustein - Officer | Grant or award | Restricted Stock Units | 17,500 | $0.00 | - | |
| Robert Blaustein - Officer | Grant or award | Stock Options (Right to buy) | 105,000 | $0.00 | - | |
| Alan J. Russell - Officer | Option exercise | Common Stock | 5,781 | $0.00 | - | |
| Alan J. Russell - Officer | Open-market sale | Common Stock | 1,907 | $13.39 | $26K | |
| Alan J. Russell - Officer | Option exercise | Restricted Stock Units | 5,781 | $0.00 | - | |
| Alan J. Russell - Officer | Grant or award | Restricted Stock Units | 28,125 | $0.00 | - | |
| Alan J. Russell - Officer | Grant or award | Stock Option (Right to Buy) | 168,750 | $0.00 | - | |
| Kevin Koch - Officer | Option exercise | Common Stock | 17,968 | $0.00 | - | |
| Kevin Koch - Officer | Open-market sale | Common Stock | 7,972 | $13.39 | $107K | |
| Kevin Koch - Officer | Option exercise | Restricted Stock Units | 17,968 | $0.00 | - | |
| Kevin Koch - Officer | Grant or award | Restricted Stock Units | 87,500 | $0.00 | - | |
| Kevin Koch - Officer | Grant or award | Stock Option (Right to Buy) | 525,000 | $0.00 | - | |
 John R. Moore - Officer | Option exercise | Common Stock | 5,781 | $0.00 | - | |
| John R. Moore - Officer | Open-market sale | Common Stock | 2,098 | $13.39 | $28K | |
| John R. Moore - Officer | Option exercise | Restricted Stock Units | 5,781 | $0.00 | - | |
| John R. Moore - Officer | Grant or award | Restricted Stock Units | 26,875 | $0.00 | - | |
| John R. Moore - Officer | Grant or award | Stock Option (Right to Buy) | 161,250 | $0.00 | - | |
| R. Michael Carruthers - Officer | Option exercise | Common Stock | 5,781 | $0.00 | - | |
| R. Michael Carruthers - Officer | Open-market sale | Common Stock | 1,428 | $13.39 | $19K | |
| R. Michael Carruthers - Officer | Option exercise | Restricted Stock Units | 5,781 | $0.00 | - | |
| R. Michael Carruthers - Officer | Grant or award | Restricted Stock Units | 26,875 | $0.00 | - | |
| R. Michael Carruthers - Officer | Grant or award | Stock Option (Right to Buy) | 161,250 | $0.00 | - | |
| Jonathan C. Fox | Grant or award | Common Stock | 858 | $0.00 | - | |
| Jonathan D. Root | Grant or award | Stock Option (Right to Buy) | 30,000 | $0.00 | - | |
| Kevin Koch - Officer | Option exercise | Common Stock | 10,417 | $0.00 | - | |
| Kevin Koch - Officer | Open-market sale | Common Stock | 4,276 | $16.45 | $70K | |
| Kevin Koch - Officer | Option exercise | Restricted Stock Units | 10,417 | $0.00 | - | |
| John R. Moore - Officer | Option exercise | Common Stock | 5,209 | $0.00 | - | |
| John R. Moore - Officer | Open-market sale | Common Stock | 1,930 | $16.45 | $32K | |
| John R. Moore - Officer | Option exercise | Restricted Stock Units | 5,209 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 372,578 | $20.13 | $7.50M | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 124,193 | $20.13 | $2.50M | |
| Alan J. Russell - Officer | Option exercise | Common Stock | 100,000 | $0.18 | $18K | |
| Alan J. Russell - Officer | Open-market sale | Common Stock | 100,000 | $27.37 | $2.74M | |
| Alan J. Russell - Officer | Option exercise | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Marc Semigran - Officer | Option exercise | Common Stock | 29,709 | $8.94 | $266K | |
| Marc Semigran - Officer | Open-market sale | Common Stock | 27,980 | $29.66 | $830K | |
| Marc Semigran - Officer | Open-market sale | Common Stock | 1,729 | $30.08 | $52K | |
| Marc Semigran - Officer | Option exercise | Stock Option (Right to Buy) | 29,709 | $0.00 | - | |
| R. Michael Carruthers - Officer | Option exercise | Common Stock | 70,000 | $0.71 | $50K | |
| R. Michael Carruthers - Officer | Option exercise | Stock Option (Right to Buy) | 70,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| JOANNE DONOVAN | Officer | 2,919 | $127K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Edgewise Therapeutics, Inc. (EWTX) had 20 insider filings in the last 90 days, with the most recent on 2026-08-17. The full record for EWTX runs to 47 Form 4 filings, the earliest from 2024-10-16. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of EWTX were filed in the last 90 days. 3 purchases are on record for this company.
21 insider sales of EWTX were filed in the last 90 days, totaling $9.78M.
This page tracks EWTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add EWTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
